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Abstract
Background: The invasion of colon cancer is associated with the tumor angiogenesis. Endostatin is an important
anti-angiogenic agent, and the additive effect of endostatin with a chemotherapeutic agent, cyclophosphamide, on
micrangium has not been established.
Methods: Male BALB/c strain nude mice were injected with human colorectal carcinoma cells (HCT-116). The mice
were divided into four groups (n = 15, each group) and were treated with different concentrations of endostatin
(15, 10, and 5 mg/kg/day), cyclophosphamide (20, 10, and 5 mg/kg/day), and combination of endostatin/
cyclophosphamide (15 + 20, 15 + 10, and 15 + 5 mg/kg/day). The tumor inhibition rate was evaluated, followed by
the quantification of messenger ribonucleic acid (mRNA) and protein expression of notch signaling components
NOTCH-1, NOTCH-3, NOTCH-4, JAG-1, DLL-4, Hes-1, and Hey-1 using quantitative polymerase chain reaction (qPCR).
The protein expression of NOTCH-3, JAG-1, and DLL-4 was confirmed using western blotting. Microvessel density
(MVD) was evaluated to detect micrangium following the treatment.
Results: The endostatin/cyclophosphamide-treated samples exhibited an additive effect on the tumor inhibition
rate and the microvessel count. NOTCH-1, NOTCH-3, NOTCH-4, JAG-1, Hes-1, and Hey-1 expression levels were
highly correlated and downregulated in the treated samples, whereas DLL-4 expression was upregulated that
accounted for its anti-angiogenic property.
Conclusions: The combination treatment of colon cancer with endostatin and a chemotherapeutic agent,
cyclophosphamide proves to be an efficient therapeutic strategy to inhibit the rapid vasculature formation
confirmed by the differential expression of notch signaling components.
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Background
Colon cancer forms the third most prevalent cancer in
the world, and its progression is critically dependant on
the angiogenesis [1]. Angiogenesis forms an important
factor in the rapid expansion of tumors by promoting
the process of metastasis [2, 3]. The anti-angiogenesis
therapy to culminate cancer has now become one of the
potential fields of study [4]. Endostatin, an angiogenesis
inhibitor, is a naturally occurring cleaved product of
carboxyl-terminal of collagen XVIII [5]. Endostatin is re-
ported to suppress the angiogenesis and endothelial cell
proliferation, thereby inhibiting the angiogenic prolifera-
tion of tumor cells [5]. However, the clinical trials have
produced mixed results on the effect of endostatin in
the tumor growth [6–9]. Endostatin exhibits anti-tumor
property and apoptosis in tumor cells, but some of the
independent studies have revealed that endostatin has
no direct cytotoxic effect on the tumor cells [6, 10–12].
The combination of endostatin with a chemotherapeutic
* Correspondence: wanggangwg21@hotmail.com
1Department of Oncology, Affiliated Zhongshan Hospital of Dalian University,
Jie Fang Street,Zhongshan District, Dalian, Liaoning 116001, Peoples’
Republic of China
Full list of author information is available at the end of the article
© 2016 Lv et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lv et al. World Journal of Surgical Oncology  (2016) 14:10 
DOI 10.1186/s12957-015-0761-9
agent reportedly enhances the efficacy of the tumor in-
hibition with the reduced side effects [13, 14].
The notch signaling pathway plays a pivotal role in the
tumor angiogenesis by promoting progenitor/stem cell
proliferation [15]. Notch signaling functions with the
combined action of a ligand receptor activity [16]. There
are four main kinds of notch receptors (NOTCH 1–4)
and five types of ligands (Delta-like ligands (DLL) 1, 3, 4
and Jagged (JAG) 1 and 2). The activation of the notch
signaling induces a conformational change by binding of
ligands to the notch receptors, which activates the γ-
secretase protein complex [16, 17]. Notch receptors are
cleaved with the activated γ-secretase to release the ac-
tive notch intracellular domain (NICD) which is translo-
cated from the nucleus to bind to the transcriptional
factors and recruits co-activators. These co-activators in-
duce the notch downstream target gene expression
(Hes-1) that finally activates the notch signaling pathway
[18]. The notch signaling pathway is aberrantly activated
during colon carcinogenesis and has been reported to be
essential in maintaining the development of the intes-
tinal cells [19].
In the present study, we examined the expression of
notch signaling receptor NOTCH-1, NOTCH-3,
NOTCH-4, ligands JAG1 and DLL-4 along with the
downstream targets Hes-1 and Hey-1 to determine the
efficacy of a combined therapeutic strategy with endosta-
tin/cyclophosphamide (CTX) to normalize the tumor
micrangium associated with colon cancer. The synergy
between endostatin and cyclophosphamide is believed to
overcome the adverse effects of a chemotherapeutic
agent and increase the activity of endostatin that is con-




The research involving animals was conducted according
to the relevant guidelines and was approved by the local
ethical committee. Male BALB/c nude mice (n = 70)
weighing 20~28.7 g were purchased from the SLAC
Company (Shanghai, China). They were caged under
optimum conditions (12 h light/dark cycle, temperature
of 22 ± 0.5 °C and humidity of 50 ± 10 %), were provided
with an appropriate diet, and were under constant in-
spection for any illness.
Culture of human colorectal carcinoma HCT-116 cells, SW-
480, and SW-620
An endotoxin-free RPMI 1640 (Gibco) supplemented
with 10 % FBS (Gibco) and penicillin-streptomycin (Life
Technologies) was used to culture human colorectal car-
cinoma cell lines (HCT-116 cells, SW-480, and SW-620)
(ATCC) and were passaged. 3 × 105 cells were cultured
for 12 h in a 25 cm2 T-flask and maintained in the above
conditions to prepare a conditioned medium for cells.
Development of a colon cancer model and endostatin/
CTX treatment
3 × 105 human colorectal carcinoma cells suspended in
0.1 ml of HBSS (Gibco) were injected into the subsplenic
capsule of the anesthetized BALB/c strain nude mice. After
recovery from the surgery, mice were divided into four ran-
dom groups (n = 15, each group). The group 1 acted as a
control and was treated with phosphate buffer saline (PBS)
(Gibco). Group 2 was injected with rh-endostatin (Biovi-
sion) alone at three different concentrations (15, 10, and
5 mg/kg/day), group 3 with CTX (Sigma-Aldrich) alone
(20, 10, and 5 mg/kg/day), and group 4 with the optimized
combinations of rh-endostatin + CTX (15 + 20, 15 + 10,
and 15 + 5 mg/kg/day). Ten mice (n = 5 each) were injected
with SW480 and SW620 cells to determine the effect of E
+ CTX treatment with respect to microsatellite stable colon
cancer cells since HCT-116 is microsatellite instability-high
(MSI-H). Following 20 days of treatment, the mice were
sacrificed and the tumor tissue was then processed for
histological examinations. The tumor tissue section (4 μm
thick) was formaldehyde-fixed and stained with H&E. The
inhibition rate of tumor growth was evaluated using the
formula, [(tumor volume of control − tumor volume of
treatment) / tumor volume of control]×100 % [15].
mRNA expression analysis using qPCR
Total RNA was extracted and converted to cDNA.
Quantitative polymerase chain reaction (qPCR) (Applied
Biosystems, Carlsbad, CA, USA) was performed to as-
sess the relative messenger ribonucleic acid (mRNA) ex-
pression levels of NOTCH-1, NOTCH-3, NOTCH-4,
JAG-1, DLL-4, Hes-1, and Hey-1 following the endosta-
tin/CTX treatment. Primer probes were acquired com-
mercially from Applied Biosystems. Actin was used as
an internal control to normalize the mean Ct values.
SDS PAGE and western blot
Tissue lysates were subjected to sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS PAGE)
according to Laemmli [20]. Fifty microgram of protein
was separated and blotted to a nitrocellulose membrane.
The blot was blocked using 5 % blocking solution (non-
fat dry milk in PBS) and then incubated with primary
antibody to NOTCH-3 (1:200; Santa Cruz, Cat. No. sc-
5593), JAG1 (1:500; Abcam, Cat. No. ab7771), DLL-4
(1:500; Abcam, Cat. No. ab7280), and anti-mouse β-
actin antibody (1:500; Santa Cruz, Cat. No. sc-4778).
The blots were then washed thrice with PBS/0.1 %
Tween followed by the incubation of blot in the second-
ary antibody which was peroxidase-conjugated goat anti-
rat IgG (1:5000; Santa Cruz, Cat. No. sc-2032). The blots
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were washed, and the proteins were detected using a
chemiluminescence system. The protein bands were vi-
sualized using ImageJ software and quantified by the
representation of protein band densities as ratios, with
respect to the internal control protein band density.
Detection of micrangium by counting microvessel density
(MVD)
The tumor sections (5 μm) from each group of treated
mice were obtained, and immunohistochemical staining
was done using nestin marker labeled with streptavidin
peroxidase (Invitrogen, USA) as described by Bottini A
et al. [21]. The stained microvessels in the tumor were
counted at ×400 magnification with the field size of
0.43 mm2. The individual vessels were counted using
ImageJ software. The average count of five fields per
tumor section in the areas with the largest number of
microvessels was considered for the analysis. The MVD
was calculated by dividing the mean microvessel count
by the microscopic field area of magnification [17].
Statistical analysis
Values are represented as means ± standard errors of the
means. One-way analysis of variance (ANOVA) was used
for the comparison of the variables, and the statistical
significance was set at p < 0.05 vs. controls using SPSS
15.0 software. One-way ANOVA was followed up by
post hoc tests for p < 0.05.
Results
Effect of endostatin/CTX on tumor growth and evaluation
of tumor inhibition rate
HCT-116-infused colorectal carcinoma mouse model
was employed to determine the effect of endostatin/
CTX on the tumor growth inhibition. The tumor inhib-
ition rate of the samples treated with endostatin alone
was evaluated to be 37.8, 28.6, and 24.7 % for the con-
centrations 15, 10, and 5 mg/kg/day, respectively. The
CTX-treated group 2 showed a comparatively high in-
hibition rate owing to its chemotherapeutic property,
i.e., 61.3, 54.3, and 48.7 % for the concentrations 20, 10,
and 5 mg/kg/day, respectively. An optimized concentra-
tion for the endostatin + CTX treatment was obtained
by selecting 15 mg/kg/day (highest inhibition rate) of
endostatin in combination with the different concentra-
tions of CTX. Endostatin + CTX exhibited highest
tumor inhibition rate (p < 0.05 vs. controls). The inhib-
ition rate was found to be 83.4, 78.5, and 76.2 % for 15
+ 20, 15 + 10, and 15 + 5 mg/kg/day, respectively (Fig. 1).
Endostatin/CTX interferes with the angiogenic function of
notch receptor and ligand expression
mRNA expression levels of NOTCH-1, NOTCH-3,
NOTCH-4, JAG-1, DLL-4, Hes-1, and Hey-1 were quan-
tified to elucidate the action of endostatin/CTX on the
notch signaling pathway in colon cancer. It was found
that DLL-4 showed a significantly higher expression
(Fig. 2c) compared to the other notch signaling
Fig. 1 Tumor inhibition rate following endostatin/CTX treatment. The graph represents tumor inhibition rate at different concentrations of
endostatin (E), CTX (C), and endostatin + CTX (E + C). The legends Conc 1, Conc 2, and Conc 3 represent the treatment concentrations of E, C, and
E + C. E was treated at 15, 10, and 5 mg/kg/day, CTX at 20, 10, and 5 mg/kg/day, and E + C at 15 + 20, 15 + 10, and 15 + 5 mg/kg/day. The
highest inhibition rate (83.4 %) was exhibited by E + C at 15 + 20 mg/kg/day. One-way ANOVA was performed, and the values were significant
with p < 0.05 vs. controls






Fig. 2 (See legend on next page.)
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components (p < 0.05 vs. controls) (Fig. 2a–d, f, g). The
expression was quantified for endostatin/CTX treatment
concentrations, and the relative expression levels are
shown in Fig. 2. It was inferred that notch receptors and
ligands with the downstream targets were expressed
positively towards the anti-angiogenic function of endo-
statin/CTX.
Notch signaling protein expression confirms the anti-
angiogenic activity of endostatin/CTX in colon cancer
The expression of notch signaling proteins, NOTCH-3,
JAG-1, and DLL-4 was confirmed using western blot
analysis. The Fig. 3 shows expression of notch signaling
proteins NOTCH-3, JAG-1, and DLL-4 in different con-
centrations of endostatin/CTX-treated samples.
NOTCH-3 and JAG-1 expression was low, and DLL-4
exhibited a prominent expression in the treated samples.
The quantified protein densities showed that endostatin
+ CTX-treated samples caused the greatest DLL-4 ex-
pression. The expression of these notch signaling pro-
teins in different colorectal cell lines (HCT-116, SW480,
SW620) was confirmed for the combination treatment
(E + CTX). HeLa cell line was used as a control.
Change in micrangium density in colon cancer-induced
mice
Differentially treated groups of colon cancer-induced
mice were counted for the microvessels. Combination of
endostatin and CTX (15 + 20 mg/kg/day) showed an
additive therapeutic effect with a significantly low micro-
vessel count and a low tumor metastatic rate (Fig. 4d).
There was a significant reduction in the microvessel
count of the endostatin-treated (15 mg/kg/day) group
(Fig. 4b). CTX-treated group (20 mg/kg/day) showed a
slight change in the microvessel count (Fig. 4c) but was
not as effective as the endostatin-treated group. The
control group treated with saline showed a greater
microvessel count indicating a high rate of tumor angio-
genesis (Fig. 4a). We obtained a mean MVD of 721
microvessels/mm2 in group 1 (control), 248 microves-
sels/mm2 in group 2 (endostatin treated), 389 microves-
sels/mm2 in group 3 (CTX treated), and 112
microvessels/mm2 in group 4 (endostatin + CTX
treated) (Fig. 4e).
Discussion
Vascularization of cancer cells promotes tumor growth
and metastasis [22, 23]. Angiogenesis is important in the
(See figure on previous page.)
Fig. 2 Effect of endostatin/cyclophosphamide treatment on the mRNA expression of NOTCH-3, JAG-1, and DLL-4. The graphs represent relative
mRNA expression levels of notch receptors, ligands, and downstream target genes at different concentrations of endostatin (E), CTX (C), and
endostatin + CTX (E + C). The legends Conc. 1, Conc. 2, and Conc. 3 represent the treatment concentrations of E, C, and E + C. E was treated at
15, 10, and 5 mg/kg/day, CTX at 20, 10, and 5 mg/kg/day, and E + C at 15 + 20, 15 + 10, and 15 + 5 mg/kg/day. a NOTCH-1 mRNA expression
level. b NOTCH-3. c NOTCH-4. d JAG-1 mRNA expression rate is similar to notch receptor expression with a greater expression in C-treated
samples and a lower expression in the E and E + C-treated samples. e DLL-4 mRNA expression levels were high in E and E + C-treated samples
whereas low in the C-treated samples. f Hes-1 mRNA expression. g Hey-1 mRNA expression. One-way ANOVA was performed, and the values
were significant with p < 0.05 vs. control
Fig. 3 Effect of endostatin/CTX on the notch signaling protein expression. The figure shows the western blot analysis of notch signaling proteins
NOTCH-3, JAG-1, and DLL-4 following endostatin/CTX treatment. E represents endostatin and CTX represents cyclophosphamide. The four lanes
represent three treatment concentrations (E at 15, 10, and 5 mg/kg/day, CTX at 20, 10, and 5 mg/kg/day and E + CTX at 15 + 20, 15 + 10, and 15
+ 5 mg/kg/day) plus control. β-actin acts as the internal control. a NOTCH-3, JAG-1, and DLL-4 expression in E, C, E + C-treated samples. b Notch
signaling protein expression in different colorectal cell lines (HCT-116, SW-480, SW-620)
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progression of cancer and higher the microvessel count,
greater the metastatic rate of cancer [24–27]. Vascular
endothelial growth factor (VEGF) is a largely studied
angiogenesis regulating growth factor that is overex-
pressed in a majority of solid tumors including colon
cancer and is considered to be one of the potential tar-
gets [28–30]. However, the development of anti-
angiogenic therapy against tumor depends on several
other factors. Notch signaling pathway is one of the im-
portant regulators of angiogenesis in tumors and is ac-
tive in colon cancer [15]. Despite an extensive research,
the role of notch signaling components is controversial
in its function towards the tumor angiogenesis [31, 32].
The notch receptors and ligands are differentially
expressed on activation of the notch signaling pathway
and contribute individually towards the physiological
and pathological conditions [33–35].
Endostatin inhibits angiogenesis, and ample reports
prove the efficiency of endostatin as an anti-angiogenic
agent in cancer cell progression [4–7, 36]. Endostatin
produces additive effects with the conventional chemo-
therapy agents, thereby reducing the adverse effects
caused by these agents [13, 14, 37]. However, the effi-
ciency of the combined therapy could be deteriorated
due to the individual or combined toxicities [11, 38].
The tumor cells sometimes become resistant to
chemotherapy due to the changing genome, but endo-
statin has a cytostatic effect and is less susceptible to
the drug resistance, thus making the combination
therapy more effective [38, 39].
In this study, we demonstrated the effect of endo-
statin/CTX in the colon cancer inhibition and anti-
angiogenesis through notch signaling pathway. The




Fig. 4 Nestin positive microvessels. a Controls with 721 microvessels/mm2. b Endostatin treated with 248 microvessels/mm2. c CTX treated with 389
microvessels/mm2. d Endostatin + CTX treated with 112 microvessels/mm2. e Bar chart representing average microvessel counts/mm2, p < 0.05 vs.
control. Values are represented as mean + SD
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inhibited the growth of tumor (Fig. 1) and reduced
the microvessel count (Fig. 4d). The endostatin treat-
ment did not have a direct effect on tumor growth
(Fig. 1) but reduced the microvessel count owing to
its anti-angiogenic property (Fig. 4b). The CTX-
treated group showed a greater tumor inhibition rate
(Fig. 1) than the endostatin-treated group, and the
microvessel counts were greater (Fig. 4c). These ob-
servations show that endostatin/CTX combination
therapy is effective in inhibition of tumor growth as
well as in the inhibition of neovascularization. The
combination therapy brings together the individual ef-
fect of endostatin as an anti-angiogenic agent and the
effect of CTX towards the inhibition of tumor
growth. However, CTX has shown positive result as
an anti-angiogenic chemotherapeutic agent [40, 44]
and hence to further establish the anti-angiogenic
property of endostatin/CTX, the mRNA and protein
expression of notch signaling components (NOTCH-
3, JAG-1, and DLL-4) were studied.
Reports indicate that NOTCH-3, JAG-1, and DLL-4
are among the most altered notch signaling genes in
cancer [40]. The expression of NOTCH-3 and JAG-1 is
highly correlated and found to be upregulated in cancer.
DLL-4 inhibition promotes the formation of new blood
vessels that establishes the role of DLL-4 against tumor
angiogenesis [33–35, 41]. We quantified the expression
levels of these notch signaling components to confirm
the function of endostatin/CTX in the colon cancer
angiogenesis. The endostatin/CTX (E + C) combination
therapy (15 + 20 mg/kg/day) downregulated the
NOTCH-3 and JAG-1 whereas upregulated the DLL-4
mRNA and protein expression (Fig. 3). The endostatin
(E) and CTX (C)-treated samples exhibited almost simi-
lar expression levels for NOTCH-3, JAG-1, and DLL-4
that confirms the additive effect of the combination
therapy against tumor angiogenesis. The observations
also confirm that the endostatin and CTX alone inhibit
the neovascularization through the notch signaling path-
way. The upregulation of DLL-4 in the treated samples
confirms its anti-angiogenic ability which is in compli-
ance with the previous reports [35, 41, 42] and resolves
the contradictions relating notch signaling pathway and
its effect in tumor angiogenesis.
The MVD was performed for the concentrations of endo-
statin and CTX that provided the maximum tumor inhib-
ition rate (Fig. 4). There is only a difference of 136
microvessels/mm2 between the endostatin-treated and
endostatin + CTX-treated samples, whereas the CTX-
treated samples exhibited a greater microvessel count
(Fig. 4a, d). These variations indicate that CTX is not pri-
marily involved in anti-angiogenesis but its combination
with the endostatin enhances the effect drastically. MVD
was performed using nestin marker to detect the
micrangium. Nestin has been particularly reported as an ef-
ficient marker to detect the presence of newly formed
micrangium in colorectal cancer [43]. Further study is es-
sential to elucidate the mechanism of CTX on the colon
cancer angiogenesis. The activity of endostatin with the
other potent chemotherapeutic agents might also open
novel prospects in the development of cancer therapy.
Conclusions
To conclude, endostatin combined with the cyclophos-
phamide was found to be drastically effective in reducing
the microvessel count and significantly increased the
tumor inhibition rate in colon cancer. The anti-
angiogenic property of the endostatin/CTX was con-
firmed with the expression of notch signaling compo-
nent. This therapeutic strategy might prove to be a
beacon of hope to curb the tumor angiogenesis.
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